Dextrose Bp

This article discusses the use of Dextrose BP in clinical trials for cancer treatments. Dextrose BP, a solution for infusion, is being utilized as a placebo in studies investigating new therapies for hepatocellular carcinoma and small-cell lung cancer. These trials aim to evaluate the efficacy and safety of various drug combinations in improving patient outcomes.

Table of Contents

What is DEXTROSE BP?

DEXTROSE BP is a medical solution used as a placebo in clinical trials[1][2]. A placebo is a substance that looks like a real medicine but doesn’t contain any active ingredients. It’s often used in research to help determine the true effects of the drug being studied.

The “BP” in DEXTROSE BP stands for “British Pharmacopoeia,” which is a collection of quality standards for medicines in the United Kingdom. This indicates that the dextrose solution meets specific quality and purity standards.

Use in Clinical Trials

DEXTROSE BP is being used as a placebo in several clinical trials, including studies on cancer treatments. For example:

  • In a study on liver cancer (hepatocellular carcinoma), DEXTROSE BP is used as a placebo to compare with new treatments[1].
  • In another study on small-cell lung cancer, DEXTROSE BP is again used as a placebo to compare with experimental treatments[2].

In these trials, some patients receive the actual treatment being studied, while others receive DEXTROSE BP as a placebo. This helps researchers determine how effective the new treatment is compared to no treatment at all.

Administration

DEXTROSE BP is typically administered as a solution for infusion. This means it’s given directly into a vein through an intravenous (IV) line[1][2]. The frequency and duration of administration can vary depending on the specific clinical trial. For instance:

  • In the liver cancer study, it’s given every 3 weeks for 12 months[1].
  • In the lung cancer study, it’s administered every 4 weeks for up to 24 months[2].

Safety and Side Effects

As DEXTROSE BP is essentially a sugar solution, it’s generally considered safe for most people when used as directed. However, as with any medical procedure, there can be risks associated with IV administration, such as infection or irritation at the injection site. It’s important to note that any side effects experienced during a clinical trial should be reported to the research team, even if you’re receiving the placebo.

Important Considerations

If you’re participating in a clinical trial using DEXTROSE BP as a placebo, here are some important points to keep in mind:

  1. You may not know whether you’re receiving the actual treatment or the placebo. This is often referred to as “blinding” and is an important part of many clinical trials.
  2. Even though DEXTROSE BP is a placebo, it’s crucial to follow all instructions given by the research team regarding its administration and any follow-up procedures.
  3. If you have diabetes or any other condition affected by blood sugar levels, make sure to inform the research team, as regular infusions of dextrose could potentially affect your blood sugar.
  4. Remember that participating in a clinical trial, even if you receive the placebo, contributes valuable information to medical research.

If you have any questions or concerns about DEXTROSE BP or its use in a clinical trial you’re participating in, don’t hesitate to ask your healthcare provider or the research team for more information.

Aspect Details
Drug Name Dextrose BP
Role in Trials Placebo (control substance)
Administration Intravenous (IV) use
Cancer Types Studied Hepatocellular Carcinoma, Limited Stage Small-Cell Lung Cancer
Trial Objectives Assess efficacy and safety of cancer treatments compared to placebo
Key Outcomes Measured Recurrence-free survival, Overall survival, Progression-free survival
Treatment Duration 12-24 months, with additional follow-up

Ongoing Clinical Trials on Dextrose Bp

  • Study on the Effectiveness of Durvalumab and Bevacizumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

    Recruiting

    3 1 1
    Austria France Germany Italy Poland
  • Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Belgium Czechia Germany Italy The Netherlands Poland +1

Glossary

  • Hepatocellular Carcinoma (HCC): A type of liver cancer that begins in the main type of liver cell (hepatocyte).
  • Small-Cell Lung Cancer (SCLC): A fast-growing type of lung cancer that usually starts in the bronchi (center of the chest).
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Recurrence-free survival (RFS): The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients diagnosed with the disease are still alive.
  • Progression-free survival (PFS): The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.
  • Intravenous (IV): Administered directly into a vein.
  • Chemoradiation therapy: A treatment that combines chemotherapy with radiation therapy.
  • Durvalumab: A type of immunotherapy drug used to treat certain types of cancer.
  • Bevacizumab: A cancer treatment drug that works by slowing or stopping the formation of new blood vessels.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-durvalumab-and-bevacizumab-for-patients-with-liver-cancer-at-high-risk-of-recurrence-after-surgery-or-ablation/
  2. http://clinicaltrials.eu/trial/study-of-durvalumab-and-tremelimumab-for-patients-with-limited-stage-small-cell-lung-cancer-after-chemoradiation-therapy/